Karyopharm (KPTI) Stock Jumps 10% on Mixed Trial Data

Key Takeaways: Selinexor Trial Results

Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 10% after the company announced mixed results from its Phase 3 SENTRY trial. The study evaluated selinexor combined with ruxolitinib for treating myelofibrosis, a type of bone marrow cancer. The trial successfully met one of its two primary goals.

Trial Data Overview

The study achieved its first primary endpoint, demonstrating a statistically significant improvement in spleen volume reduction. At week 24, 50% of patients receiving the selinexor combination achieved a 35% or more reduction in spleen volume, compared to 28% in the ruxolitinib-only group. However, the trial did not meet its second primary endpoint, as the improvement in total symptom score was not statistically significant between the two treatment arms.

Market Impact and Future Outlook

Despite the mixed results, the trial revealed a promising overall survival signal, with a hazard ratio of 0.43 for the combination arm. Karyopharm plans to discuss the data with the FDA for a potential new drug application. The company also announced a private placement expected to generate approximately $30 million, indicating investor confidence. The combination showed a manageable safety profile with no new signals.

Summary

Investors reacted positively to the successful spleen volume endpoint and encouraging survival data, leading to the stock's rise. The company's next steps, particularly its discussions with the FDA, will be critical in determining the future regulatory path for selinexor in this indication.

FAQ

Q: Why did Karyopharm stock increase despite mixed results?
A: The stock rose because the trial met a crucial primary endpoint for spleen volume reduction and showed a promising overall survival signal, which investors viewed as significant positive developments.

Q: What is the next step for Karyopharm?
A: Karyopharm plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the trial data and the possibility of filing a supplemental new drug application.

Source: Investing.com